stage IVb bladder cancer

Summary

stage IVb bladder cancer (MONDO:0004182) is a cancer and 3 clinical trials. Top therapeutic interventions include nivolumab. A subtype of urinary bladder carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	stage IVb bladder cancer
Mondo ID	MONDO:0004182
DOID	DOID:7315
NCIT	C9368
UMLS	C1336362
MedGen	277737
Is cancer (heuristic)	yes

Also known as: Jewett-Marshall stage D2 bladder cancer · Jewett-Marshall stage D2 urinary bladder cancer · Jewett-Marshall stage D2 urinary bladder carcinoma · stage IVB bladder cancer · stage IVB urinary bladder cancer · stage IVB urinary bladder carcinoma

Disease family

This is a subtype of urinary bladder carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › urinary bladder carcinoma › stage IVb bladder cancer

Related subtypes (8): bladder adenocarcinoma, bladder squamous cell carcinoma, bladder urachal carcinoma, urinary bladder small cell neuroendocrine carcinoma, superficial urinary bladder carcinoma, bladder transitional cell carcinoma, childhood bladder carcinoma, bladder small cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
EARLY_PHASE1	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03229278	PHASE1	COMPLETED	Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
NCT02646319	EARLY_PHASE1	COMPLETED	Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
NCT02735512	Not specified	TERMINATED	MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NIVOLUMAB	4	1